Create, articulate, and execute strategy for all product development activities within advanced stage vaccine development program, leading a cross-functional matrixed team spanning Research, Chemistry Manufacturing Controls (CMC), Clinical, Regulatory, Immunology, Non-Clinical, Commercial, and Medical Affairs • Implemented first ever internally funded R&D program, managed program budget $200M+ and aligned first-ever publication plan, scientific platform, and data-to-label-claims map• Established, envisioned and secured first-ever Breakthrough Therapy (FDA) and PRIME (EMA) designations for Emergent

Authored commercial voice on product core team for 5 programs, ranging from Phase 2 to Pre-Clinical and provided strategic commercial assessments for key business development opportunities• Devised commercial valuation for $270M vaccine acquisition, including revenue generation products and multiple late-stage products in new business areas• Launched gap closure plans for regulatory interactions related to a combination product and delivery device development requirements, achieving resolutions without impact to timeline• Pioneered Business Unit's Portfolio Prioritization initiative project, funneling 100 potential areas down to 12 critical, prioritized programs• Shaped and administered 2 strategic market assessments determining business strategy on entering disease areas

• Drove development of Global commercial launch strategy for Entyvio subcutaneous (SC), identify key inputs for strategic brand planning, and partner with commercial insights to aggregate insights and deliver on focus areas for launch• Provided Global Commercial leadership of Phase 3 Life Cycle Management program for injectable biologic, developing device requirements for patient self-administration and influencing clinical protocols to ensure studies are successfully designed with commercial needs. Deliver business recommendations on prioritizing projects• Collaborated and assessed lifecycle management opportunities through partnership with R&D, Medical, US Commercial, Business Development, Regional Leadership, Regulatory, Market Access, and Global Outcomes • Drove business development deal through internal governance, develop and align potential forecast with relevant leaders and regions, gain buy-in from Senior Executives to execute deal for new technology platform for company pipeline product; work across Therapeutic Areas to identify additional opportunities for platform• Managed, tracked and controled Global Commercial budget across Emerging Markets, Europe and US, build leadership awareness of budgetary items, and ensure overall delivery of organizational program commitments• Engaged and drove Commercial voice with Clinical Development and Regulatory on Phase II and Phase III Pediatric program• Partnered with Market Access and Regional Commercial Leads to select key countries for positive reimbursement outcomes and promotional claims• Updated and strengthened Entyvio SC forecast at a global and regional level, while aligning with R&D on a full evaluation of the program’s eNPV; Evaluated market development and patient needs to deliver reconciled forecast • Orchestrated cross-functional decision to overhaul Entyvio SC Instructions for Use by hiring health literacy team to build patient-friendly guide and locating a subject matter expert to consult

• Executive project leader of large-scale, cross-functional initiatives, totaling ~$225MM of savings over two years, spanning all business units, brands, and functions to achieve financial project goals across the enterprise• Responsible for creating and coordinating with executives and executive staff, delivering quarterly disclosure presentations for CFO, including Q&A for disclosure, and development of materials for Shareholder’s meeting• Partnered with cross-functional executives to assess, prioritize, and implement new enterprise opportunities to drive efficiencies within Takeda’s operations, resulting in more than $5MM in additional savings • Collaborated with critical stakeholders within core workstreams to effectively communicate expectations and results, manage risks, and measure and track effectiveness and efficiency of strategic initiatives • Selected as a subject matter expert (SME) and key leader within the Launch Excellence and Readiness task force to globally align Takeda’s launch readiness planning and processes across regions and business units

• Managed P&L, ranging from $310-$751MM annually during 5-year period, from partner income across Gastroenterology, Metabolic, Cardiovascular, Oncology, Women’s Health and Respiratory• Single-Point-of-Contact for Takeda’s relationships with Global and Regional Pharmaceutical companies (forecasting sales and purchases, project management of new and existing market registrations, assessment of current market trends, oversight of supply chain operations, and expansion of partnership opportunities) resulting in a single, aligned Takeda viewpoint• Teamed with Global Marketing to assess Phase 3 IBD compound’s potential growth opportunities around patient target, product profile, competitive landscape, life cycle opportunities, positioning and messaging• Teamed with internal Development organization to assess partner’s Pediatric clinical protocols and delivered necessary clinical materials and supplies to initiate clinical trials• Lead efforts to measure asset value to Takeda through repatriation and outlicensing deals to drive organization to a Go/No Go decision based on asset maximization strategies • Assessed potential oncology out-license deal in Emerging Markets and ran due diligence team • Partnered with IP to renew relevant partner and corporate trademarks in countries to optimize Takeda’s brands and worked to maximize overall value• Lead global cross-functional deal assessment team of targeted repatriation across 33 countries which resulted in immediate revenue to Takeda markets

Diabetes Sales and Patient Strategies--pre-launch product

Gastroenterology Consumer Marketing--built CRM program for Prevacid and Dexilant

Pediatric Gastroenterology Sales and Consumer Marketing